Skip to content
NBlaz – Lifestyle
Author:
InflaRx N.V.
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 4, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026
May 1, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 28, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
April 9, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
March 12, 2026
←
Previous Page
1
2